Compugen rises on royalty deal with AstraZeneca
Source: SeekingAlpha
2025-12-17 07:58:04 ET
More on Compugen, AstraZeneca
- AstraZeneca: A Rare Compound Growth Opportunity In Biopharma
- Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
- AstraZeneca PLC 2025 Q3 - Results - Earnings Call Presentation
- AstraZeneca's Enhertu and Genentech's Perjeta combo gains breast cancer approval
- RSV shots for infants reportedly under FDA scrutiny
Read the full article on Seeking Alpha
For further details see:
Compugen rises on royalty deal with AstraZeneca
Compugen Ltd.
NASDAQ: CGEN
CGEN Trading
4.78% G/L:
$2.30 Last:
224,627 Volume:
$2.19 Open:
CGEN Latest News
CGEN Stock Data
$165,050,413
90,614,080
N/A
90
N/A
Biotechnology & Life Sciences
Healthcare
IL
Holon
